Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Inflammatory Bowel Diseases

Free Subscription Articles published in Clin Gastroenterol Hepatol Retrieve available abstracts of 289 articles: HTML format

Single Articles

May 2026
1. ASWANI-OMPRAKASH T, Devi J, Balasubramaniam M, Ananthakrishnan AN, et al
   Patient-Inclusive Recruitment in Inflammatory Bowel Disease Trials: Key Takeaways From the 2025 Strategic Alliance for Intercultural Advocacy in GI-American Gastroenterological Association Asian Clinical Research Roundtable.
   Clin Gastroenterol Hepatol. 2026;24:1209-1214.
   PubMed    
   
   
   April 2026
2. KIM T, Nguyen I, Thomas N, Picker M, et al
   Intestinal inflammation impacts gestational weight gain in women with inflammatory bowel disease and growth in offspring.
   Clin Gastroenterol Hepatol. 2026 Apr 20:S1542-3565(26)00289.
   PubMed    
   
   
   
3. PALMELA C, Reves J, Frias-Gomes C, Morao B, et al
   Use of Intestinal Ultrasound in a Tight monitoring approach in Crohn's disease: a multicentre prospective study.
   Clin Gastroenterol Hepatol. 2026 Apr 15:S1542-3565(26)00279.
   PubMed     Abstract available
   
   
   
4. AHUJA D, Park SK, Qi Y, Patel SB, et al
   Treatment and Outcomes of Crohn's Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007-23.
   Clin Gastroenterol Hepatol. 2026 Apr 15:S1542-3565(26)00280.
   PubMed     Abstract available
   
   
   
5. MARK-CHRISTENSEN A, Kristiansen EB, Laurberg S, Erichsen R, et al
   Decreasing primary resection rates for Crohn's disease but unchanged re-resection rates: A nationwide Danish population-based cohort study from 1997 to 2021.
   Clin Gastroenterol Hepatol. 2026 Apr 9:S1542-3565(26)00246.
   PubMed     Abstract available
   
   
   
6. HANAUER SB, Colombel JF
   Reply to: Subcutaneous Infliximab and Assumptions of Response in Ileal Crohn's Disease: Does Route of Administration Matter?
   Clin Gastroenterol Hepatol. 2026 Apr 2:S1542-3565(26)00237.
   PubMed    
   
   
   
7. SANDS BE, Schreiber S, Dubinsky MC, D'Haens G, et al
   Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.
   Clin Gastroenterol Hepatol. 2026;24:1111-1120.
   PubMed     Abstract available
   
   
   March 2026
8. ALLEZ M, Bak MTJ, Brand S, Diebakate-Scordamaglia L, et al
   Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic era.
   Clin Gastroenterol Hepatol. 2026 Mar 27:S1542-3565(26)00220.
   PubMed     Abstract available
   
   
   
9. FAN D, Mao Y, Liang F, Liu Z, et al
   INTELCAPE: A Deep Learning-Powered System for Automated, High-Accuracy Crohn's Disease Diagnosis via Capsule Endoscopy.
   Clin Gastroenterol Hepatol. 2026 Mar 18:S1542-3565(26)00184.
   PubMed     Abstract available
   
   
   
10. SANDS BE, Barnes EL, D'Haens G, Hisamatsu T, et al
    Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial.
    Clin Gastroenterol Hepatol. 2026 Mar 5:S1542-3565(26)00155.
    PubMed     Abstract available
    
    
    
11. CHETWOOD JD, Little RD
    Subcutaneous Infliximab and Assumptions of Response in Ileal Crohn's Disease: Does Route of Administration Matter?
    Clin Gastroenterol Hepatol. 2026 Mar 5:S1542-3565(26)00151.
    PubMed    
    
    
    
12. AHUJA D, Yeh KH, Patel SB, Lee HH, et al
    Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2026;24:794-804.
    PubMed     Abstract available
    
    
    February 2026
13. PANACCIONE R, Panes J, Peyrin-Biroulet L, Colombel JF, et al
    Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.
    Clin Gastroenterol Hepatol. 2026 Feb 26:S1542-3565(26)00145.
    PubMed     Abstract available
    
    
    
14. NEVES JC, Leal T, Fernandes S, Sousa DC, et al
    EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS - A MULTICENTER RETROSPECTIVE STUDY.
    Clin Gastroenterol Hepatol. 2026 Feb 26:S1542-3565(26)00141.
    PubMed     Abstract available
    
    
    
15. YERUSHALMY-FELER A, Spencer EA, Dubinsky MC, Suskind DL, et al
    Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-week Multicenter Study from the Porto Group of ESPGHAN.
    Clin Gastroenterol Hepatol. 2026 Feb 17:S1542-3565(26)00138.
    PubMed     Abstract available
    
    
    
16. LEMSER CE, Koziol A, Boelt SG, MacSween N, et al
    Pre-diagnostic Changes in the Metabolome of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2026 Feb 17:S1542-3565(26)00137.
    PubMed     Abstract available
    
    
    
17. AXELRAD J, Faye AS, Soderling J, Marild K, et al
    Incidence and risk of colorectal dysplasia in patients with inflammatory bowel disease: A nationwide cohort study.
    Clin Gastroenterol Hepatol. 2026 Feb 16:S1542-3565(26)00097.
    PubMed     Abstract available
    
    
    
18. JENA A, Chatterjee A, Choudhury A, Sharma V, et al
    Effectiveness and safety of JAK inhibitors in acute severe ulcerative colitis: A systematic review and meta-analysis.
    Clin Gastroenterol Hepatol. 2026 Feb 12:S1542-3565(26)00106.
    PubMed     Abstract available
    
    
    
19. DALAL RS, Kwaning KM, Silvestri ME, Carlin AD, et al
    Comparative Effectiveness and Safety of Upadacitinib Versus Risankizumab for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2026 Feb 3:S1542-3565(26)00061.
    PubMed    
    
    
    
20. AGRAWAL M, Hansen AV, Julsgaard M, Colombel JF, et al
    Prediction of inflammatory bowel disease based on early life risk factors in a population-based cohort.
    Clin Gastroenterol Hepatol. 2026 Feb 3:S1542-3565(26)00063.
    PubMed     Abstract available
    
    
    
21. COHEN ER, Steinberg JM, Christian K
    Building and Sustaining Inflammatory Bowel Disease (IBD) Specialty Care in the Community: Insights and Solutions from the AGA IBD Community Care Initiative.
    Clin Gastroenterol Hepatol. 2026 Feb 3:S1542-3565(26)00058.
    PubMed    
    
    
    January 2026
22. TANG W, Jiang Z, Huang Y
    Multilocus heterotopic gastric mucosa mimicking Crohn's disease.
    Clin Gastroenterol Hepatol. 2026 Jan 30:S1542-3565(26)00049.
    PubMed    
    
    
    
23. PRIVITERA G, Bezzio C, Figlioli G, D'Amico F, et al
    Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.
    Clin Gastroenterol Hepatol. 2026 Jan 28:S1542-3565(26)00045.
    PubMed     Abstract available
    
    
    
24. WU RY, Xue M, Zhao Q, Jeong S, et al
    Serum IgG Response to a Conserved Domain of Commensal Flagellins Predicts Future Risk of Crohn's Disease in First-Degree Relatives.
    Clin Gastroenterol Hepatol. 2026 Jan 12:S1542-3565(25)01031.
    PubMed     Abstract available
    
    
    
25. KOCHHAR GS, Coelho-Prabhu N, Hashash JG, Shen B, et al
    AGA Clinical Practice Update on the Role of Therapeutic Endoscopy in Inflammatory Bowel Disease: Commentary.
    Clin Gastroenterol Hepatol. 2026 Jan 9:S1542-3565(25)00990.
    PubMed     Abstract available
    
    
    
26. ANJIE SI, Gecse KB, Meloni CM, Vidal-Itriago A, et al
    Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2026;24:57-68.
    PubMed     Abstract available
    
    
    
27. COELHO-PRABHU N, Ohri A, Benatzky C, Baskaran NU, et al
    Liver Transplantation Is Associated With a Reduced Risk of Colorectal Dysplasia in Patients With IBD and Concomitant PSC.
    Clin Gastroenterol Hepatol. 2026;24:181-189.
    PubMed     Abstract available
    
    
    
28. OMEDE M, Itam-Eyo A, Park A, Ikobah J, et al
    Epidemiology, Natural History, and Treatment of Inflammatory Bowel Disease in Africa: A Scoping Review.
    Clin Gastroenterol Hepatol. 2026;24:41-56.
    PubMed     Abstract available
    
    
    December 2025
29. CONSTANTINE-COOKE N, Vestergaard MV, Plevris N, Monterrubio-Gomez K, et al
    Large-scale clustering of longitudinal fecal calprotectin and C-reactive protein profiles in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2025 Dec 29:S1542-3565(25)01069.
    PubMed     Abstract available
    
    
    
30. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Week 12 Reduction in MM-SES-CD is Predictive of Delayed Response to Upadacitinib in Crohn's disease.
    Clin Gastroenterol Hepatol. 2025 Dec 26:S1542-3565(25)01067.
    PubMed     Abstract available
    
    
    
31. KIM SH, Qi Y, Banegas MP, Kappelman MD, et al
    Prevalence and Impact of Social Risk in Patients With Inflammatory Bowel Diseases: National Estimates From the United States.
    Clin Gastroenterol Hepatol. 2025;23:2588-2596.
    PubMed     Abstract available
    
    
    
32. MATHIEU N, Hupe M, Heluwaert F, Riviere P, et al
    PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission.
    Clin Gastroenterol Hepatol. 2025;23:2597-2606.
    PubMed     Abstract available
    
    
    
33. DAMAS OM, Leo M, Colina N, Mijares M, et al
    A Pilot Randomized Control Trial to Assess the Adjunctive Effect of Diet on Response to Advanced Therapies in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2025;23:2579-2587.
    PubMed     Abstract available
    
    
    
34. AKIYAMA S, Park SH, Baek JE, Kanai S, et al
    Prevalence and Outcomes of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: A Multinational Study across Asia.
    Clin Gastroenterol Hepatol. 2025 Dec 1:S1542-3565(25)01004.
    PubMed     Abstract available
    
    
    November 2025
35. HE Z, Sun Y, Huang H, Fu T, et al
    Circulating Metabolite Signatures Linking Physical Activity to Inflammatory Bowel Disease Risk and Interactions with Genetic Susceptibility.
    Clin Gastroenterol Hepatol. 2025 Nov 24:S1542-3565(25)00997.
    PubMed     Abstract available
    
    
    
36. VUYYURU SK, Hanzel J, Brar MS, Danese S, et al
    Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Nov 18:S1542-3565(25)00988.
    PubMed     Abstract available
    
    
    
37. SUN J, Marild K, Bergman D, Ebrahimi F, et al
    Histologic remission and mortality in patients with inflammatory bowel disease: a nationwide cohort study.
    Clin Gastroenterol Hepatol. 2025 Nov 13:S1542-3565(25)00943.
    PubMed     Abstract available
    
    
    
38. KAYAL M, Jimenez D, Huang J, Spencer EA, et al
    Comparable 12-Week and Superior 24-Week Remission with Risankizumab vs Ustekinumab for Crohn's-Like Disease of the Pouch.
    Clin Gastroenterol Hepatol. 2025 Nov 7:S1542-3565(25)00935.
    PubMed    
    
    
    
39. WEWER MD, Lophaven S, Lakatos PL, Gonczi L, et al
    Long-term disease course of Crohn's disease in a prospective European population-based inception cohort - an Epi-IBD cohort study.
    Clin Gastroenterol Hepatol. 2025 Nov 3:S1542-3565(25)00931.
    PubMed     Abstract available
    
    
    October 2025
40. FERNANDES RG, Kim DH, Ruddick-Collins L, Vasudevan A, et al
    Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from Australasia.
    Clin Gastroenterol Hepatol. 2025 Oct 29:S1542-3565(25)00927.
    PubMed     Abstract available
    
    
    
41. LOUIS E, Sebastian S, Siegmund B, Bossuyt P, et al
    Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study.
    Clin Gastroenterol Hepatol. 2025 Oct 13:S1542-3565(25)00891.
    PubMed     Abstract available
    
    
    
42. ANDRADE P, Mascarenhas M, Mendes F, Rosa B, et al
    AI-ASSISTED CAPSULE ENDOSCOPY FOR DETECTION OF ULCERS AND EROSIONS IN CROHN'S DISEASE: A MULTICENTER VALIDATION STUDY.
    Clin Gastroenterol Hepatol. 2025 Oct 9:S1542-3565(25)00861.
    PubMed     Abstract available
    
    
    
43. BEN HUR D, Issaschar G, Moshe R, Lebedenko B, et al
    Risk of Age-related and Disease-related Complications and Mortality in Elderly-onset Inflammatory Bowel Disease: A Population-based Study.
    Clin Gastroenterol Hepatol. 2025;23:1982-1990.
    PubMed     Abstract available
    
    
    September 2025
44. UEKADO H, Watanabe D, Kodama Y
    Syphilitic Proctitis Mimicking Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2025 Sep 29:S1542-3565(25)00849.
    PubMed    
    
    
    
45. REZAZADEH ARDABILI A, Le Berre C, Colombel JF
    Advanced therapies in Crohn's disease: a critical appraisal of location-based efficacy.
    Clin Gastroenterol Hepatol. 2025 Sep 22:S1542-3565(25)00839.
    PubMed    
    
    
    
46. LOVETT GC, Schulberg JD, Hamilton A, Wright EK, et al
    Long-term Results of Drug Treatment for Crohn's Disease Strictures.
    Clin Gastroenterol Hepatol. 2025 Sep 17:S1542-3565(25)00805.
    PubMed     Abstract available
    
    
    
47. PANACCIONE R, Melmed GY, Drobne D, Kaur M, et al
    Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment.
    Clin Gastroenterol Hepatol. 2025 Sep 13:S1542-3565(25)00797.
    PubMed     Abstract available
    
    
    
48. PRENTICE R, Burns M, Bell SJ
    Novel tools for assessment of neurocognitive outcomes in infants born to women with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2025 Sep 13:S1542-3565(25)00794.
    PubMed    
    
    
    
49. WEWER MD, Soderling J, Ludvigsson JF, Myrelid P, et al
    Early ileocecal resection or tumor necrosis factor inhibitor in Crohn's disease: Replication in a Swedish cohort.
    Clin Gastroenterol Hepatol. 2025 Sep 11:S1542-3565(25)00762.
    PubMed    
    
    
    
50. WANG Z, Hoffert Y, Zhang W, Kantasiripitak W, et al
    Infliximab and ustekinumab clearance better predict endoscopic outcomes than trough concentrations in Crohn's disease.
    Clin Gastroenterol Hepatol. 2025 Sep 7:S1542-3565(25)00750.
    PubMed     Abstract available
    
    
    
51. HANZEL J, Vuyyuru SK, Bressler B, Samaan MA, et al
    Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT trial.
    Clin Gastroenterol Hepatol. 2025 Sep 2:S1542-3565(25)00741.
    PubMed     Abstract available
    
    
    August 2025
52. CARON B, Jairath V, Sands BE, Rubin DT, et al
    International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice.
    Clin Gastroenterol Hepatol. 2025 Aug 27:S1542-3565(25)00739.
    PubMed     Abstract available
    
    
    
53. CAI L, Wittrup E, Minoccheri C, Hiatt T, et al
    Artificial Intelligence for Quantifying Endoscopic Mucosal Ulceration in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Aug 18:S1542-3565(25)00655.
    PubMed     Abstract available
    
    
    
54. BUISSON A, Serrero M, Altwegg R, Guilmoteau T, et al
    Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study.
    Clin Gastroenterol Hepatol. 2025 Aug 18:S1542-3565(25)00700.
    PubMed     Abstract available
    
    
    
55. BOURGONJE AR, Mian P
    Advancing Proactive Therapeutic Drug Monitoring with Model-Informed Precision Dosing in Pediatric Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Aug 7:S1542-3565(25)00666.
    PubMed    
    
    
    
56. HO AH, Choi D, Mathew AJ, McDermott A, et al
    Real-World Experience of Upadacitinib Reinduction and High Dose Maintenance Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2025 Aug 7:S1542-3565(25)00668.
    PubMed     Abstract available
    
    
    
57. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2025 Aug 6:S1542-3565(25)00322.
    PubMed     Abstract available
    
    
    
58. SANDS BE, Schreiber S, Danese S, Kierkus J, et al
    A Phase 2 Study of MORF-057, an Oral alpha4beta7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2025 Aug 4:S1542-3565(25)00648.
    PubMed     Abstract available
    
    
    
59. BLOEMEN H, Livanos AE, Martins A, Dean R, et al
    Anti-integrin alphavbeta6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.
    Clin Gastroenterol Hepatol. 2025;23:1612-1622.
    PubMed     Abstract available
    
    
    July 2025
60. PALMELA C, Torres J, Frias-Gomes C, Allocca M, et al
    The EXTENT Study: Results from an International Expert Delphi Consensus to define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Jul 28:S1542-3565(25)00637.
    PubMed     Abstract available
    
    
    
61. PANACCIONE R, Regueiro M, Lee SD, Atreya R, et al
    Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.
    Clin Gastroenterol Hepatol. 2025 Jul 28:S1542-3565(25)00643.
    PubMed     Abstract available
    
    
    
62. BAK MTJ, Demers K, van Ruler O, Pierik MJ, et al
    Preoperative body composition parameters are associated with postoperative outcomes in patients with Crohn's disease.
    Clin Gastroenterol Hepatol. 2025 Jul 28:S1542-3565(25)00636.
    PubMed     Abstract available
    
    
    
63. HONAP S, St-Pierre J, Colwill M, Patel K, et al
    Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis.
    Clin Gastroenterol Hepatol. 2025 Jul 26:S1542-3565(25)00639.
    PubMed     Abstract available
    
    
    
64. LEE HH, Yuan Y, Boland BS, Chang JT, et al
    Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn's Disease: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2025 Jul 23:S1542-3565(25)00615.
    PubMed     Abstract available
    
    
    
65. SNINSKY JA, Sansgiry S, Taylor T, Perrin M, et al
    The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes.
    Clin Gastroenterol Hepatol. 2025 Jul 22:S1542-3565(25)00624.
    PubMed     Abstract available
    
    
    
66. ABDALLA M, Eberhardson M, Landerholm K, Andersson RE, et al
    Impact of inflammatory bowel disease and primary sclerosing cholangitis on colorectal cancer risk:national cohort study.
    Clin Gastroenterol Hepatol. 2025 Jul 22:S1542-3565(25)00621.
    PubMed     Abstract available
    
    
    
67. IACUCCI M, Nardone OM, Ditonno I, Capobianco I, et al
    Advancing Inflammatory Bowel Disease-driven Colorectal Cancer Management: Molecular Insights and Endoscopic Breakthroughs Towards Precision Medicine.
    Clin Gastroenterol Hepatol. 2025 Jul 22:S1542-3565(25)00616.
    PubMed     Abstract available
    
    
    
68. JAIRATH V, D'Haens G, Sands BE, Travis S, et al
    Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial.
    Clin Gastroenterol Hepatol. 2025 Jul 14:S1542-3565(25)00581.
    PubMed     Abstract available
    
    
    
69. DALAL RS, Carlin AD, Cabral HJ, Clarke LM, et al
    One-Year Comparative Effectiveness and Safety of Upadacitinib Versus Risankizumab for Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Jul 7:S1542-3565(25)00568.
    PubMed    
    
    
    
70. IBRAHIM MK, Cohen R, Chhibba T, Kumar M, et al
    An International Multicenter Study of Native and Immigrant South Asian Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Jul 7:S1542-3565(25)00544.
    PubMed     Abstract available
    
    
    
71. YARUR AJ, Reinisch W, Chang S, Gecse KB, et al
    Efficacy of etrasimod in ulcerative colitis: analysis of ELEVATE UC 52 and ELEVATE UC 12 by baseline endoscopic severity.
    Clin Gastroenterol Hepatol. 2025 Jul 4:S1542-3565(25)00542.
    PubMed     Abstract available
    
    
    
72. ATTAUABI M, Madsen GR, Bendtsen F, Seidelin JB, et al
    Multidimensional Patient-Reported Outcomes and Quality of Life at Diagnosis of IBD: A Population-Based Inception Cohort Study.
    Clin Gastroenterol Hepatol. 2025;23:1418-1427.
    PubMed     Abstract available
    
    
    June 2025
73. FEUERSTEIN JD, Rubin DT, Aberra FN, Yarur A, et al
    Appropriate use and complications of corticosteroids in inflammatory bowel disease: A comprehensive review.
    Clin Gastroenterol Hepatol. 2025 Jun 28:S1542-3565(25)00535.
    PubMed     Abstract available
    
    
    
74. PATHAK P, Choudhury A, Marikanty A, Jena A, et al
    Wearable technologies in inflammatory bowel disease: A scoping review.
    Clin Gastroenterol Hepatol. 2025 Jun 27:S1542-3565(25)00532.
    PubMed     Abstract available
    
    
    
75. BUSTOS BI, Miquel JF, Hernandez-Rocha C
    Letter Response to: Ioannou S, Beecham A, Gomez L, et al. Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol August 2024:S1542-3565(24)00766-3.
    Clin Gastroenterol Hepatol. 2025 Jun 27:S1542-3565(25)00527.
    PubMed    
    
    
    
76. DURICOVA D, Sonnenberg E, Augustijns P, Mitrova K, et al
    Upadacitinib in Mother with Inflammatory Bowel Disease: Placental Transfer and Breast milk Excretion.
    Clin Gastroenterol Hepatol. 2025 Jun 24:S1542-3565(25)00526.
    PubMed    
    
    
    
77. HIRTEN RP, Danieletto M, Whang JK, Landell K, et al
    Wearable Devices Identify Altered Sleep Characteristics and Sleep Trajectories in Active Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2025 Jun 23:S1542-3565(25)00522.
    PubMed     Abstract available
    
    
    
78. AGRAWAL M, Allin KH, Hansen AV, Colombel JF, et al
    Primary EBV infection in late childhood, but not in adulthood, is associated with lower risk of inflammatory bowel disease in a population-based cohort.
    Clin Gastroenterol Hepatol. 2025 Jun 21:S1542-3565(25)00521.
    PubMed    
    
    
    
79. STROM A, Jansson S, Wewer MD, Burisch J, et al
    Perianal Disease in Pediatric-Onset Crohn's Disease: Incidence, Disease Course, and Long-Term Outcomes.
    Clin Gastroenterol Hepatol. 2025 Jun 13:S1542-3565(25)00492.
    PubMed     Abstract available
    
    
    
80. DE VOOGD F, Beek KJ, Pruijt M, van Rijn K, et al
    Intestinal Ultrasound and Its Advanced Modalities in Characterizing Strictures in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Jun 12:S1542-3565(25)00489.
    PubMed     Abstract available
    
    
    
81. HONAP S, Temido MJ, Shakweh E, Badrulhisham F, et al
    Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study.
    Clin Gastroenterol Hepatol. 2025 Jun 10:S1542-3565(25)00465.
    PubMed     Abstract available
    
    
    
82. SAMNANI S, Ray CM, Gill P, Stein L, et al
    Diagnostic Accuracy of Non-Invasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Jun 2:S1542-3565(25)00455.
    PubMed     Abstract available
    
    
    
83. CALAFAT M, Kochar B, Ananthakrishnan AN
    A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2025;23:1088-1101.
    PubMed     Abstract available
    
    
    
84. SINGH S, Poulsen GJ, Bisgaard TH, Bonfils L, et al
    Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study.
    Clin Gastroenterol Hepatol. 2025;23:1204-1215.
    PubMed     Abstract available
    
    
    May 2025
85. KANG B, Kim ES, Choi S, Choe BH, et al
    Proactive Drug Monitoring versus Clinically-based Dosing for Endoscopic Healing in Pediatric Crohn's Disease Receiving Infliximab.
    Clin Gastroenterol Hepatol. 2025 May 14:S1542-3565(25)00412.
    PubMed     Abstract available
    
    
    
86. BACCARELLA A, Patel T, Conrad MA, Macchi M, et al
    Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2025 May 14:S1542-3565(25)00404.
    PubMed     Abstract available
    
    
    
87. COHEN NA, Sror N, Naseer M, Bettenworth D, et al
    DIAGNOSIS AND MANAGEMENT OF UPPER GASTROINTESTINAL INVOLVEMENT IN ADULT PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW.
    Clin Gastroenterol Hepatol. 2025 May 14:S1542-3565(25)00416.
    PubMed     Abstract available
    
    
    
88. HONAP S, Patel K, Peyrin-Biroulet L
    Acute Severe Ulcerative Colitis Clinical Trial Design - Author's Reply.
    Clin Gastroenterol Hepatol. 2025 May 10:S1542-3565(25)00361.
    PubMed    
    
    
    
89. D'AMICO F, Peyrin-Biroulet L, Danese S
    Concomitant medications and advanced therapies in ulcerative colitis: patient-centric approach for optimal disease control.
    Clin Gastroenterol Hepatol. 2025 May 8:S1542-3565(25)00336.
    PubMed    
    
    
    
90. VUYYURU SK, Shaban N, Yuan Y, Honap S, et al
    Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review with Meta-analysis.
    Clin Gastroenterol Hepatol. 2025 May 6:S1542-3565(25)00329.
    PubMed     Abstract available
    
    
    April 2025
91. SINGH A, Bhardwaj A, Sharma R, Jain D, et al
    Effectiveness and Safety of Tofacitinib in Biologic-Naive Elderly Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2025 Apr 15:S1542-3565(25)00292.
    PubMed    
    
    
    
92. LARSON C, Berinstein JA, Tedesco N, Seidelin JB, et al
    Postoperative Outcomes in Tofacitinib-treated Patients with Acute Severe Ulcerative Colitis Undergoing Colectomy.
    Clin Gastroenterol Hepatol. 2025 Apr 14:S1542-3565(25)00287.
    PubMed     Abstract available
    
    
    
93. HUANG Z, Diao N, Guo Q, Li M, et al
    Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naive Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Apr 14:S1542-3565(25)00285.
    PubMed     Abstract available
    
    
    
94. LE BERRE C, Jairath V, Panaccione R, Bourreille A, et al
    Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review.
    Clin Gastroenterol Hepatol. 2025 Apr 10:S1542-3565(25)00278.
    PubMed     Abstract available
    
    
    
95. ANAND E, Devi J, Ballard DH, Joshi S, et al
    Defining radiological healing in perianal fistulising Crohn's Disease: a TOpClass global expert Delphi consensus.
    Clin Gastroenterol Hepatol. 2025 Apr 8:S1542-3565(25)00248.
    PubMed     Abstract available
    
    
    
96. KRUGER AJ, Dormont F, Capit N, Schilsky S, et al
    Biologic switch timing and risk of infection in patients with ulcerative colitis/Crohn's disease: a retrospective study.
    Clin Gastroenterol Hepatol. 2025 Apr 7:S1542-3565(25)00245.
    PubMed     Abstract available
    
    
    March 2025
97. MADSEN GR, Attauabi M, Ilvemark JFKF, Theede K, et al
    Intestinal Ultrasound Findings and Their Prognostic Value in Early Crohn's Disease - a Copenhagen IBD Cohort Study.
    Clin Gastroenterol Hepatol. 2025 Mar 11:S1542-3565(25)00158.
    PubMed     Abstract available
    
    
    
98. DEVI J, Xu A, Stone M, Patel A, et al
    Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study.
    Clin Gastroenterol Hepatol. 2025 Mar 7:S1542-3565(25)00154.
    PubMed     Abstract available
    
    
    February 2025
99. MEYER A, Marty L, Drouin J, Weill A, et al
    Risks of 75 major congenital malformations after in utero exposure to thiopurines and anti-TNF for maternal inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2025 Feb 26:S1542-3565(25)00147.
    PubMed     Abstract available
    
    
    
100. PANACCIONE R, Ferrante M, Dotan I, Panes J, et al
     Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.
     Clin Gastroenterol Hepatol. 2025 Feb 3:S1542-3565(25)00082.
     PubMed     Abstract available
     
     
     
101. CHEDID V, Targownik L, Damas OM, Balzora S, et al
     Culturally Sensitive and Inclusive IBD Care.
     Clin Gastroenterol Hepatol. 2025;23:440-453.
     PubMed     Abstract available
     
     
     
102. BURISCH J, Claytor J, Hernandez I, Hou JK, et al
     The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable.
     Clin Gastroenterol Hepatol. 2025;23:386-395.
     PubMed     Abstract available
     
     
     
103. FUDMAN DI, McConnell RA, Ha C, Singh S, et al
     Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.
     Clin Gastroenterol Hepatol. 2025;23:454-468.
     PubMed     Abstract available
     
     
     
104. BATTAT R, Chang JT, Loftus EV Jr, Sands BE, et al
     IBD Matchmaking: Rational Combination Therapy.
     Clin Gastroenterol Hepatol. 2025;23:469-479.
     PubMed     Abstract available
     
     
     
105. CLICK B, Cross RK, Regueiro M, Keefer L, et al
     The IBD Clinic of Tomorrow: Holistic, Patient-Centric, and Value-based Care.
     Clin Gastroenterol Hepatol. 2025;23:419-427.
     PubMed     Abstract available
     
     
     
106. ANANTHAKRISHNAN AN, Whelan K, Allegretti JR, Sokol H, et al
     Diet and Microbiome-Directed Therapy 2.0 for IBD.
     Clin Gastroenterol Hepatol. 2025;23:406-418.
     PubMed     Abstract available
     
     
     January 2025
107. SEHGAL P, Lewis JD, Pickett-Blakely O, Nandi N, et al
     Safety and clinical effectiveness of GLP1 receptor agonists in inflammatory bowel disease patients.
     Clin Gastroenterol Hepatol. 2025 Jan 30:S1542-3565(25)00073.
     PubMed    
     
     
     
108. CALDERA F, Kane S, Long M, Hashash JG, et al
     Non-colorectal Cancer Screening and Vaccinations in Patients with Inflammatory Bowel Disease: Expert Review.
     Clin Gastroenterol Hepatol. 2025 Jan 10:S1542-3565(25)00020.
     PubMed     Abstract available
     
     
     
109. CATTANEO EF, Shmidt E, Shitrit AB, Nara P, et al
     Twin Pregnancies in Inflammatory Bowel Disease are Associated with Increased Adverse Outcomes.
     Clin Gastroenterol Hepatol. 2025 Jan 3:S1542-3565(24)01130.
     PubMed    
     
     
     
110. MITROVA K, Julsgaard M, Augustijns P, Cerna K, et al
     Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations.
     Clin Gastroenterol Hepatol. 2025;23:163-165.
     PubMed     Abstract available
     
     
     
111. JULSGAARD M, Wieringa JW, Baunwall SMD, Bibby BM, et al
     Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy.
     Clin Gastroenterol Hepatol. 2025;23:134-143.
     PubMed     Abstract available
     
     
     December 2024
112. SIGALL BONEH R, Navas-Lopez VM, Hussey S, Pujol-Muncunill G, et al
     Modified Crohn's Disease Exclusion Diet Maintains Remission in Pediatric Crohn's Disease; Randomized Controlled Trial.
     Clin Gastroenterol Hepatol. 2024 Dec 26:S1542-3565(24)01131.
     PubMed     Abstract available
     
     
     
113. LEE HH, Solitano V, Singh S, Ananthakrishnan AN, et al
     Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists.
     Clin Gastroenterol Hepatol. 2024 Dec 26:S1542-3565(24)01132.
     PubMed     Abstract available
     
     
     
114. TAKENAKA K, Hisamatsu T, Kobayashi T, Yamamoto H, et al
     Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; a prospective multicenter study.
     Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01084.
     PubMed     Abstract available
     
     
     
115. GRIFFITHS BJ, Desborough MJR, Duijvestein M, D'Haens GRA, et al
     Hypercoagulation after Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study.
     Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01085.
     PubMed     Abstract available
     
     
     
116. DANESE S, Rothenberg ME, Lim JJ, Ding HT, et al
     A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.
     Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01096.
     PubMed     Abstract available
     
     
     
117. ZHENG J, Zhang X, Zhang L, Li L, et al
     Serum Albumin and Its Trajectory Are Associated with Therapeutic Outcomes in Ulcerative Colitis.
     Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01091.
     PubMed     Abstract available
     
     
     
118. KIM D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, et al
     Healthcare and Prescription Medication Affordability for Inflammatory Bowel Disease in the US in 2023.
     Clin Gastroenterol Hepatol. 2024 Dec 15:S1542-3565(24)01092.
     PubMed    
     
     
     
119. YANG Y, Carrero JJ
     Reply to "Kidney Failure, Inflammatory Bowel Disease and Colectomy ".
     Clin Gastroenterol Hepatol. 2024 Dec 15:S1542-3565(24)01077.
     PubMed    
     
     
     
120. HONAP S, Jairath V, Sands BE, Dulai PS, et al
     Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints.
     Clin Gastroenterol Hepatol. 2024 Dec 14:S1542-3565(24)01082.
     PubMed     Abstract available
     
     
     
121. JACOBSEN HA, Karachalia-Sandri A, Ebert AC, Allin KH, et al
     Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-Based Cohort Study 1997-2020.
     Clin Gastroenterol Hepatol. 2024 Dec 13:S1542-3565(24)01071.
     PubMed     Abstract available
     
     
     
122. SINOPOULOU V, Nigam GB, Gordon M, Ganeshan M, et al
     Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-Analysis.
     Clin Gastroenterol Hepatol. 2024 Dec 13:S1542-3565(24)01073.
     PubMed     Abstract available
     
     
     
123. DALAL RS, Cabral HJ, Carlin A, Ilse MP, et al
     Outcomes After Dose Intensification of Risankizumab for Crohn's Disease.
     Clin Gastroenterol Hepatol. 2024 Dec 9:S1542-3565(24)01067.
     PubMed    
     
     
     
124. DI VINCENZO F, Quintero MA, Mendygral P, Abreu MT, et al
     Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research.
     Clin Gastroenterol Hepatol. 2024;22:2357-2361.
     PubMed    
     
     
     
125. LEWIS JD, Brensinger CM, Parlett LE, Hurtado-Lorenzo A, et al
     Provider Specialization in Inflammatory Bowel Diseases: Quality of Care and Outcomes.
     Clin Gastroenterol Hepatol. 2024;22:2475-2486.
     PubMed     Abstract available
     
     
     
126. OUTTIER A, Louis E, Dewit O, Reenaers C, et al
     Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study.
     Clin Gastroenterol Hepatol. 2024;22:2468-2474.
     PubMed     Abstract available
     
     
     November 2024
127. CHEN J, Dan L, Yuan S, Fu T, et al
     Dietary antioxidant capacity, genetic susceptibility and polymorphism, and inflammatory bowel disease risk in a prospective cohort.
     Clin Gastroenterol Hepatol. 2024 Nov 5:S1542-3565(24)00980.
     PubMed     Abstract available
     
     
     
128. COSQUER GL, Kirchgesner J, Joseph CGS, Seksik P, et al
     Risk of incident cancer in patients with Inflammatory Bowel Disease with prior breast cancer: a multicenter cohort study.
     Clin Gastroenterol Hepatol. 2024 Nov 4:S1542-3565(24)00981.
     PubMed     Abstract available
     
     
     
129. JESSEN B, T Tordai M, Siegmund B
     Peripheral tumor necrosis factor production is a predictor for remission under adalimumab in Crohn's disease.
     Clin Gastroenterol Hepatol. 2024 Nov 2:S1542-3565(24)00982.
     PubMed    
     
     
     October 2024
130. ALSOUD D, Sabino J, Ferrante M, Verstockt B, et al
     Calibration, Clinical Utility and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00958.
     PubMed     Abstract available
     
     
     
131. CALDERA F, Singh S, Zona EE, Ramirez Ramirez O, et al
     Patients with Inflammatory Bowel Disease are at Increased Risk for Complications of Herpes Zoster.
     Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00960.
     PubMed     Abstract available
     
     
     
132. ZINGER A, Choi D, Choi N, Fear E, et al
     Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's Disease from a Large Tertiary Center.
     Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00968.
     PubMed     Abstract available
     
     
     
133. DICKEN Q, Omede M, Ananthakrishnan AN
     Outcomes Of Long-term Tumor Necrosis Factor Alpha Inhibitor Therapy Beyond Ten Years In Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Oct 23:S1542-3565(24)00956.
     PubMed    
     
     
     
134. LOFTUS EV JR, Torres J, Hou JK, Kahi C, et al
     Introduction to Thirteenth Issue CGH The Future of Inflammatory Bowel Disease Care.
     Clin Gastroenterol Hepatol. 2024 Oct 23:S1542-3565(24)00946.
     PubMed    
     
     
     
135. SANGMO L, Quraishi B, Rajauria P, Giselbrecht E, et al
     Natural history of clinically-suspected isolated perianal fistulizing Crohn's disease.
     Clin Gastroenterol Hepatol. 2024 Oct 23:S1542-3565(24)00954.
     PubMed    
     
     
     
136. LI CP, Gau SY, Chang HC
     Kidney Failure, Inflammatory Bowel Disease and Colectomy.
     Clin Gastroenterol Hepatol. 2024 Oct 23:S1542-3565(24)00951.
     PubMed    
     
     
     
137. BENARD MV, de Goffau MC, Blonk J, Hugenholtz F, et al
     Fecal Microbiota Transplantation Outcome and Gut Microbiota Composition in Ulcerative Colitis: a Systematic Review and Meta-analysis.
     Clin Gastroenterol Hepatol. 2024 Oct 21:S1542-3565(24)00907.
     PubMed     Abstract available
     
     
     
138. CLAYTOR JD, Faith JJ
     Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor?
     Clin Gastroenterol Hepatol. 2024 Oct 21:S1542-3565(24)00909.
     PubMed    
     
     
     
139. AHUJA D, Zou G, Solitano V, Syal G, et al
     No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis.
     Clin Gastroenterol Hepatol. 2024 Oct 10:S1542-3565(24)00877.
     PubMed     Abstract available
     
     
     September 2024
140. COLOMBEL JF, Lacerda AP, Irving PM, Panaccione R, et al
     Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
     Clin Gastroenterol Hepatol. 2024 Sep 24:S1542-3565(24)00860.
     PubMed     Abstract available
     
     
     
141. BUCHNER AM, Farraye FA, Iacucci M
     American Gastroenterological Association Clinical Practice Update on Endoscopic Scoring Systems in Inflammatory Bowel Disease: Commentary.
     Clin Gastroenterol Hepatol. 2024 Sep 19:S1542-3565(24)00718.
     PubMed     Abstract available
     
     
     
142. HONAP S, Zou G, Danese S, Peyrin-Biroulet L, et al
     Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges.
     Clin Gastroenterol Hepatol. 2024 Sep 18:S1542-3565(24)00829.
     PubMed     Abstract available
     
     
     August 2024
143. WEWER MD, Letnar G, Andersen KK, Malham M, et al
     Thiopurines and the Risk of Cancer in Patients with Inflammatory Bowel Disease and Reference Individuals without Inflammatory Bowel Disease - A Danish Nationwide Cohort Study (1996-2018).
     Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00772.
     PubMed     Abstract available
     
     
     
144. GOODSALL TM, An YK, Andrews JM, Begun J, et al
     Reliability of intestinal ultrasound for evaluating Crohn's disease activity using point-of-care and central reading.
     Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00773.
     PubMed     Abstract available
     
     
     
145. REVES J, Fernandez-Clotet A, Ordas I, Buisson A, et al
     Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn's disease.
     Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00769.
     PubMed     Abstract available
     
     
     
146. SHEHAB M, Alrashed F, Alsayegh A, Aldallal U, et al
     Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis.
     Clin Gastroenterol Hepatol. 2024 Aug 23:S1542-3565(24)00767.
     PubMed     Abstract available
     
     
     
147. IOANNOU S, Beecham A, Gomez L, Dauer R, et al
     Ancestral diversity in pharmacogenomics affects treatment for Hispanic/Latine populations with inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2024 Aug 22:S1542-3565(24)00766.
     PubMed     Abstract available
     
     
     
148. MCLAUGHLIN JF, Linville T, Jester TW, Marciano TA, et al
     Travel Time to Treating Center is Associated with Diagnostic Delay in Pediatric Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Aug 22:S1542-3565(24)00761.
     PubMed     Abstract available
     
     
     
149. HANNA LN, Anandabaskaran S, Iqbal N, Geldof J, et al
     Perianal fistulising Crohn's disease: utilising the TOpClass classification in clinical practice to provide targeted individualised care.
     Clin Gastroenterol Hepatol. 2024 Aug 10:S1542-3565(24)00692.
     PubMed     Abstract available
     
     
     
150. KAHN-BOESEL O, Araka E, Anyane-Yeboa A, Ufere NN, et al
     The Discrepant Visual Representation of Inflammatory Bowel Diseases in the Internet and Media.
     Clin Gastroenterol Hepatol. 2024;22:1555-1560.
     PubMed    
     
     
     
151. BARNES EL, Karachalia Sandri A, Herfarth HH, Jess T, et al
     Antibiotic Use in the 12 Months Prior to Ileal Pouch-Anal Anastomosis Increases the Risk for Pouchitis.
     Clin Gastroenterol Hepatol. 2024;22:1678-1686.
     PubMed     Abstract available
     
     
     July 2024
152. MAGRO F, Peyrin-Biroulet L, Sands BE, Danese S, et al
     Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod [106/120 characters, including spaces].
     Clin Gastroenterol Hepatol. 2024 Jul 30:S1542-3565(24)00681.
     PubMed     Abstract available
     
     
     
153. ERNEST-SUAREZ K, Murguia-Favela LE, Constantinescu C, Fitzpatrick T, et al
     LIVE ROTAVIRUS VACCINATION APPEARS LOW-RISK IN INFANTS BORN TO MOTHERS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS.
     Clin Gastroenterol Hepatol. 2024 Jul 30:S1542-3565(24)00677.
     PubMed     Abstract available
     
     
     
154. OHARA J, Maeda Y, Ogata N, Kuroki T, et al
     Automated Neutrophil Quantification and Histological Score Estimation in Ulcerative Colitis.
     Clin Gastroenterol Hepatol. 2024 Jul 24:S1542-3565(24)00668.
     PubMed     Abstract available
     
     
     
155. MA C, Solitano V, Danese S, Jairath V, et al
     THE FUTURE OF CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE.
     Clin Gastroenterol Hepatol. 2024 Jul 16:S1542-3565(24)00635.
     PubMed     Abstract available
     
     
     
156. CHAVANNES M, Dolinger MT, Cohen-Mekelburg S, Abraham B, et al
     AGA Clinical Practice Update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary.
     Clin Gastroenterol Hepatol. 2024 Jul 10:S1542-3565(24)00454.
     PubMed     Abstract available
     
     
     
157. LOPES EW, Turpin W, Croitoru K, Colombel JF, et al
     Prediction and Prevention of Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Jul 10:S1542-3565(24)00597.
     PubMed    
     
     
     
158. SILVERMAN AL, Shung D, Stidham RW, Kochhar GS, et al
     How Artificial Intelligence Will Transform Clinical Care, Research, and Trials for Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Jul 9:S1542-3565(24)00598.
     PubMed     Abstract available
     
     
     
159. GAO L, Fang K, Dong X, Bai J, et al
     Additional yield of random biopsy in patients with inflammatory bowel disease: A systematic review and meta-analysis.
     Clin Gastroenterol Hepatol. 2024 Jul 5:S1542-3565(24)00556.
     PubMed     Abstract available
     
     
     
160. INNOCENTI T, Rocco C, Lynch EN, Milla M, et al
     Applicability of the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) to ulcerative colitis: a preliminary study.
     Clin Gastroenterol Hepatol. 2024 Jul 4:S1542-3565(24)00607.
     PubMed    
     
     
     
161. ROCHA CH, Turpin W, Borowski K, Stempak JM, et al
     After surgically induced remission, ileal and colonic mucosa-associated microbiota predicts Crohn's disease recurrence.
     Clin Gastroenterol Hepatol. 2024 Jul 3:S1542-3565(24)00592.
     PubMed     Abstract available
     
     
     
162. ATREYA R, Neurath MF
     Biomarkers for Personalizing IBD Therapy: The Quest Continues.
     Clin Gastroenterol Hepatol. 2024;22:1353-1364.
     PubMed     Abstract available
     
     
     
163. KHAKOO NS, Beecham AH, Lyu J, Quintero MA, et al
     Early Life and Childhood Environmental Exposures, More Than Genetic Predisposition, Influence Age of Diagnosis in a Diverse Cohort of 2952 Patients With IBD.
     Clin Gastroenterol Hepatol. 2024;22:1462-1474.
     PubMed     Abstract available
     
     
     
164. TORRES J, Hanauer SB
     EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way?
     Clin Gastroenterol Hepatol. 2024;22:1377-1378.
     PubMed    
     
     
     June 2024
165. BUISSON A, Junda J, Vignette J, Lecoq E, et al
     Development and validation of a score to assess transmural healing and response in patients with Crohn's disease.
     Clin Gastroenterol Hepatol. 2024 Jun 20:S1542-3565(24)00546.
     PubMed     Abstract available
     
     
     
166. TORRES J, Mahadevan U
     Editorial: Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy with Inflammatory Bowel Disease: Stop the Disease, not the Drug!
     Clin Gastroenterol Hepatol. 2024 Jun 13:S1542-3565(24)00543.
     PubMed    
     
     
     
167. WONG SY, Rowan C, Brockmans ED, Law CC, et al
     Perianal fistulizing Crohn's disease-associated anorectal and fistula cancers: systematic review and expert consensus.
     Clin Gastroenterol Hepatol. 2024 Jun 11:S1542-3565(24)00504.
     PubMed     Abstract available
     
     
     May 2024
168. CAENEPEEL C, Deleu S, Vazquez Castellanos JF, Arnauts K, et al
     RIGOROUS DONOR SELECTION FOR FMT IN ACTIVE ULCERATIVE COLITIS: KEY LESSONS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY.
     Clin Gastroenterol Hepatol. 2024 May 22:S1542-3565(24)00492.
     PubMed     Abstract available
     
     
     
169. GARGALLO-PUYUELO CJ, Ricart E, Iglesias E, de Francisco R, et al
     SEX-RELATED DIFFERENCES IN THE PHENOTYPE AND COURSE OF INFLAMMATORY BOWEL DISEASE: SEXEII STUDY OF ENEIDA.
     Clin Gastroenterol Hepatol. 2024 May 21:S1542-3565(24)00487.
     PubMed     Abstract available
     
     
     
170. YANG Y, Ludvigsson JF, Forss A, Faucon AL, et al
     Risk of kidney failure in patients with inflammatory bowel disease undergoing colectomy: a nationwide cohort study.
     Clin Gastroenterol Hepatol. 2024 May 20:S1542-3565(24)00484.
     PubMed     Abstract available
     
     
     
171. ITZKOWITZ SH, Jiang Y, Villagra C, Colombel JF, et al
     Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: SAPPHIRE Registry.
     Clin Gastroenterol Hepatol. 2024 May 18:S1542-3565(24)00479.
     PubMed     Abstract available
     
     
     
172. DAI C, Huang YH, Jiang M
     Antibiotic Use and the Risk of Pouchitis after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.
     Clin Gastroenterol Hepatol. 2024 May 17:S1542-3565(24)00491.
     PubMed    
     
     
     
173. XUE M, Leibovitzh H, Jingcheng S, Neustaeter A, et al
     Environmental Factors Associated with Risk of Crohn's Disease Development in the CCC-GEM Project.
     Clin Gastroenterol Hepatol. 2024 May 15:S1542-3565(24)00450.
     PubMed     Abstract available
     
     
     
174. AXELRAD JE, Hashash JG, Itzkowitz SH
     AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients with Malignancy: Commentary.
     Clin Gastroenterol Hepatol. 2024 May 14:S1542-3565(24)00354.
     PubMed     Abstract available
     
     
     
175. PUDIPEDDI A, Paramsothy S, Kariyawasam V, Paramsothy R, et al
     Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial.
     Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00426.
     PubMed     Abstract available
     
     
     
176. MOULTON CD, Young AH, Hart AL
     Targeting durable remission of fatigue in inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00433.
     PubMed    
     
     
     
177. AGRAWAL M, Stordal K, Hansen AV, Ostensson M, et al
     Breastfeeding duration is not associated with offspring inflammatory bowel disease risk in three population-based birth cohorts.
     Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00416.
     PubMed     Abstract available
     
     
     
178. FUMERY M, Caron B, Hebuterne X, Altwegg R, et al
     Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
     Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00423.
     PubMed     Abstract available
     
     
     
179. SANDS BE, D'Haens G, Panaccione R, Regueiro M, et al
     Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
     Clin Gastroenterol Hepatol. 2024 May 7:S1542-3565(24)00405.
     PubMed     Abstract available
     
     
     
180. ALI S, Pasternak B, Moses J, Suskind DL, et al
     Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn's Disease.
     Clin Gastroenterol Hepatol. 2024 May 7:S1542-3565(24)00406.
     PubMed     Abstract available
     
     
     
181. ROBLIN X, Moschetti E, Barrau M, Cheifetz AS, et al
     Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn's disease.
     Clin Gastroenterol Hepatol. 2024 May 3:S1542-3565(24)00402.
     PubMed    
     
     
     
182. SOFIA MA, Feuerstein JD, Narramore L, Chachu KA, et al
     White Paper: American Gastroenterological Association Position Statement: The Future of IBD Care in the United States-Removing Barriers and Embracing Opportunities.
     Clin Gastroenterol Hepatol. 2024;22:944-955.
     PubMed     Abstract available
     
     
     
183. SINGH S, Velayos FS, Rubin DT
     Common Instances of Low-value Care in Inflammatory Bowel Diseases.
     Clin Gastroenterol Hepatol. 2024;22:923-932.
     PubMed     Abstract available
     
     
     
184. MAHMUD O, Fatimi AS, Mahar MU, Jahangir A, et al
     Sphingosine 1-Phosphate Receptor Modulators are Effective in Patients With Moderately to Severely Active Ulcerative Colitis and a Prior Biologic Exposure: A Meta-Analysis of Randomized Controlled Trials.
     Clin Gastroenterol Hepatol. 2024;22:1139-1141.
     PubMed    
     
     
     April 2024
185. PAPAMICHAEL K, Centritto A, Guillo L, Hier J, et al
     Higher adalimumab concentration is associated with complete fistula healing in patients with perianal fistulizing Crohn's disease.
     Clin Gastroenterol Hepatol. 2024 Apr 29:S1542-3565(24)00397.
     PubMed    
     
     
     March 2024
186. BAGER P, Hvas CL, Dahlerup JF
     Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy with Modanfinil or Vitamin Therapy with Thiamine.
     Clin Gastroenterol Hepatol. 2024 Mar 18:S1542-3565(24)00283.
     PubMed    
     
     
     
187. PRENTICE R, Flanagan E, Wright EK, Gibson PR, et al
     Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero.
     Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00252.
     PubMed     Abstract available
     
     
     
188. PEYRIN-BIROULET L, Panaccione R, Louis E, Atreya R, et al
     Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
     Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00253.
     PubMed     Abstract available
     
     
     
189. COLOMBEL JF, Hisamatsu T, Atreya R, Bresso F, et al
     Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
     Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00254.
     PubMed     Abstract available
     
     
     
190. GUPTA A, Peyrin-Biroulet L, Ananthakrishnan AN
     Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
     Clin Gastroenterol Hepatol. 2024;22:499-512.
     PubMed     Abstract available
     
     
     
191. BOYD T, Ananthakrishnan AN
     Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.
     Clin Gastroenterol Hepatol. 2024;22:659-661.
     PubMed     Abstract available
     
     
     February 2024
192. AXELRAD JE, Rubin DT
     The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Feb 29:S1542-3565(24)00108.
     PubMed    
     
     
     
193. WIJNANDS AM, Penning de Vries BBL, Lutgens MWMD, Bakhshi Z, et al
     Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2024 Feb 29:S1542-3565(24)00214.
     PubMed     Abstract available
     
     
     
194. NARULA N, Wong ECL, Dulai PS, Patel J, et al
     Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated with Low Risk of Disease Progression.
     Clin Gastroenterol Hepatol. 2024 Feb 28:S1542-3565(24)00212.
     PubMed     Abstract available
     
     
     
195. DUAN R, Zhang C, Li G, Li J, et al
     Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis.
     Clin Gastroenterol Hepatol. 2024 Feb 27:S1542-3565(24)00218.
     PubMed     Abstract available
     
     
     
196. BRENNER EJ, Weaver KN, Zhang X, Kastl AJ, et al
     Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2024 Feb 16:S1542-3565(24)00203.
     PubMed     Abstract available
     
     
     
197. POLYDORIDES AD
     Assessment and significance of histologic activity in Crohn disease.
     Clin Gastroenterol Hepatol. 2024 Feb 14:S1542-3565(24)00196.
     PubMed    
     
     
     
198. KOCHAR B, Ananthakrishnan AN, Ritchie CS
     Pharmacoequity for Older Adults With Inflammatory Bowel Diseases.
     Clin Gastroenterol Hepatol. 2024;22:209-214.
     PubMed    
     
     
     
199. CONSTANT BD, Albenberg L, Mitchel EB, De Zoeten EF, et al
     Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey.
     Clin Gastroenterol Hepatol. 2024;22:423-426.
     PubMed    
     
     
     
200. LAPP SL, Bewtra M, Lewis JD
     Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough.
     Clin Gastroenterol Hepatol. 2024;22:420-422.
     PubMed    
     
     
     
201. CORSETTI M, Ballou S
     Symptom Subgroups Taking Into Account Psychological Burden Predicts Irritable Bowel Syndrome Disease Impact and Burden: A Step Forward?
     Clin Gastroenterol Hepatol. 2024;22:237-240.
     PubMed    
     
     
     
202. TE GROEN M, Derks M, den Broeder N, Peters C, et al
     Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study.
     Clin Gastroenterol Hepatol. 2024;22:357-367.
     PubMed     Abstract available
     
     
     January 2024
203. KEDIA S, Virmani S, Bajaj A, Markandey M, et al
     Coconut water induces clinical remission in mild to moderate ulcerative colitis: double-blind placebo controlled trial.
     Clin Gastroenterol Hepatol. 2024 Jan 24:S1542-3565(24)00088.
     PubMed     Abstract available
     
     
     
204. AHUJA D, Luo J, Qi Y, Syal G, et al
     Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn's Disease: Secondary Analysis of the PYRAMID Registry.
     Clin Gastroenterol Hepatol. 2024 Jan 10:S1542-3565(24)00047.
     PubMed     Abstract available
     
     
     
205. MEYER A, Miranda S, Drouin J, Weill A, et al
     Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2024 Jan 8:S1542-3565(24)00010.
     PubMed     Abstract available
     
     
     
206. MOULTON CD, Young AH, Hart AL
     Modafinil for severe fatigue in inflammatory bowel disease: a prospective case series.
     Clin Gastroenterol Hepatol. 2024 Jan 6:S1542-3565(24)00011.
     PubMed    
     
     
     
207. VUYYURU SK, Nguyen TM, Murad MH, Narula N, et al
     Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
     Clin Gastroenterol Hepatol. 2024 Jan 5:S1542-3565(24)00003.
     PubMed     Abstract available
     
     
     
208. KATIBIAN DJ, Solitano V, Polk DB, Nguyen T, et al
     Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
     Clin Gastroenterol Hepatol. 2024;22:22-33.
     PubMed     Abstract available
     
     
     
209. LEMMENS P, Louis E, Van Moerkercke W, Pouillon L, et al
     Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.
     Clin Gastroenterol Hepatol. 2024;22:154-163.
     PubMed     Abstract available
     
     
     
210. DE MELLO MK, Freitas Queiroz NS, Papamichael K
     Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?
     Clin Gastroenterol Hepatol. 2024;22:200-201.
     PubMed    
     
     
     December 2023
211. AGRAWAL M, Midya V, Maroli A, Magee J, et al
     Per- and poly-fluoroalkyl substances (PFAS) exposure is associated with later occurrence of inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2023 Dec 26:S1542-3565(23)01055.
     PubMed    
     
     
     
212. NIGAM GB, Limdi JK, Bate S, Hamdy S, et al
     Fecal Urgency in Ulcerative Colitis: Impact on Quality of Life and Psychological Well-being in Active and Inactive Disease States.
     Clin Gastroenterol Hepatol. 2023 Dec 25:S1542-3565(23)01054.
     PubMed    
     
     
     
213. ELMASRY S, Ha C
     Evidence-Based Approach to the Management of Mild Crohn's Disease.
     Clin Gastroenterol Hepatol. 2023 Dec 20:S1542-3565(23)00949.
     PubMed    
     
     
     
214. MCCURDY J, Munir J, Parlow S, Reid J, et al
     Development of an MRI-based prediction model for anti-TNF treatment failure in perianal Crohn's disease: A multicenter study.
     Clin Gastroenterol Hepatol. 2023 Dec 18:S1542-3565(23)01035.
     PubMed     Abstract available
     
     
     
215. MURTHY SK, Bernstein CN, Nguyen GC, Jairath V, et al
     Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2023 Dec 18:S1542-3565(23)01036.
     PubMed    
     
     
     
216. SINGH S, Allegretti J, Nersesova Y, Serra S, et al
     Meeting Summary: AGA Roundtable on Clinical Trial Design in Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2023 Dec 16:S1542-3565(23)01033.
     PubMed    
     
     
     
217. ZINGER A, Choi D, Choi N, Cohen RD, et al
     Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data from a Large Tertiary Center.
     Clin Gastroenterol Hepatol. 2023 Dec 6:S1542-3565(23)00998.
     PubMed    
     
     
     
218. SOLITANO V, Schaeffer DF, Hogan M, Casteele NV, et al
     Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity.
     Clin Gastroenterol Hepatol. 2023 Dec 4:S1542-3565(23)00969.
     PubMed     Abstract available
     
     
     
219. SCHREGEL I, Ramos GP, Ioannou S, Culver E, et al
     Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study.
     Clin Gastroenterol Hepatol. 2023;21:3448-3450.
     PubMed    
     
     
     November 2023
220. ARMUZZI A, Cross RK, Lichtenstein GR, Hou J, et al
     Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
     Clin Gastroenterol Hepatol. 2023 Nov 29:S1542-3565(23)00956.
     PubMed     Abstract available
     
     
     
221. KAWADA T
     Fecal calprotectin profiles in Crohn's disease: a longitudinal data analysis.
     Clin Gastroenterol Hepatol. 2023 Nov 28:S1542-3565(23)00953.
     PubMed    
     
     
     
222. MAGRO F, Protic M, De Hertogh G, Chan LS, et al
     Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
     Clin Gastroenterol Hepatol. 2023 Nov 20:S1542-3565(23)00948.
     PubMed     Abstract available
     
     
     
223. JAIRATH V, Yarur A, Osterman MT, James A, et al
     ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse.
     Clin Gastroenterol Hepatol. 2023 Nov 9:S1542-3565(23)00912.
     PubMed     Abstract available
     
     
     
224. WANG Z, Verstockt B, Sabino J, Ferrante M, et al
     Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study.
     Clin Gastroenterol Hepatol. 2023;21:3188-3190.
     PubMed    
     
     
     October 2023
225. MARILD K, Soderling J, Axelrad J, Halfvarson J, et al
     Histological activity in inflammatory bowel disease and risk of serious infections: A nationwide study.
     Clin Gastroenterol Hepatol. 2023 Oct 30:S1542-3565(23)00855.
     PubMed     Abstract available
     
     
     
226. SHAH RS, Bachour S, Joseph A, Xiao H, et al
     Real World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn's Disease.
     Clin Gastroenterol Hepatol. 2023 Oct 23:S1542-3565(23)00851.
     PubMed     Abstract available
     
     
     
227. DIGNASS A, Stremmel W, Horynski M, Poyda O, et al
     Modified-release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-blind, Randomized, Placebo-controlled Trials.
     Clin Gastroenterol Hepatol. 2023 Oct 6:S1542-3565(23)00771.
     PubMed     Abstract available
     
     
     
228. JANGI S, Hsia K, Zhao N, Kumamoto CA, et al
     Dynamics of the Gut Mycobiome in Patients with Ulcerative Colitis.
     Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00762.
     PubMed     Abstract available
     
     
     
229. A B, M N, B P, M F, et al
     Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study.
     Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00766.
     PubMed    
     
     
     
230. GEEM D, Hercules D, Pelia RS, Venkateswaran S, et al
     Progression of Pediatric Crohn's Disease is Associated with Anti-TNF Timing and BMI Z-Score Normalization.
     Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00757.
     PubMed     Abstract available
     
     
     
231. ULRICH JA, Habash NW, Ismail YA, Tremaine WJ, et al
     Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease.
     Clin Gastroenterol Hepatol. 2023;21:2901-2907.
     PubMed     Abstract available
     
     
     
232. BICKSTON SJ, Kaur H
     Higher Rates of Smoking Cessation as a Cause for a Rise in Pouchitis.
     Clin Gastroenterol Hepatol. 2023;21:2988-2989.
     PubMed    
     
     
     
233. YARUR AJ, McGovern D, Abreu MT, Cheifetz A, et al
     Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
     Clin Gastroenterol Hepatol. 2023;21:2908-2917.
     PubMed     Abstract available
     
     
     September 2023
234. WILS P, Jairath V, Sands BE, Reinisch W, et al
     Washout periods in inflammatory bowel disease trials: A systematic literature review and proposed solutions.
     Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00747.
     PubMed    
     
     
     
235. COLOMBEL JF, Ungaro RC, Sands BE, Siegel CA, et al
     Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
     Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00746.
     PubMed     Abstract available
     
     
     
236. WILSON A, Chande N, Ponich T, Gregor JC, et al
     HLADQA1*05G>A genetic-screening promotes the safe delivery of combination therapy in inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2023 Sep 19:S1542-3565(23)00710.
     PubMed    
     
     
     
237. ODUFALU FD, Loftus EV Jr, Balzora S
     Crohn's Disease: an Equal Opportunity Burden.
     Clin Gastroenterol Hepatol. 2023 Sep 12:S1542-3565(23)00702.
     PubMed    
     
     
     
238. SOLITANO V, Moschetta A
     Metabolic dysfunction-associated steatotic liver disease (MASLD) in inflammatory bowel disease (IBD): a proposed stepwise approach.
     Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00669.
     PubMed    
     
     
     
239. CAMILLERI M, Zheng DST
     Cannabinoids and the GI Tract.
     Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00668.
     PubMed     Abstract available
     
     
     
240. DALAL RS, Kallumkal G, Cabral HJ, Bachour S, et al
     Comparative Effectiveness of Upadacitinib Versus Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.
     Clin Gastroenterol Hepatol. 2023 Sep 4:S1542-3565(23)00671.
     PubMed    
     
     
     
241. MCCURDY JD, Stwalley D, Olsen MA, Deepak P, et al
     Comparative effectiveness of biologic therapies in preventing penetrating complications in patients with Crohn's disease.
     Clin Gastroenterol Hepatol. 2023 Sep 4:S1542-3565(23)00664.
     PubMed     Abstract available
     
     
     
242. IBING S, Cho JH, Bottinger EP, Ungaro RC, et al
     Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
     Clin Gastroenterol Hepatol. 2023;21:2629-2638.
     PubMed     Abstract available
     
     
     
243. LIMKETKAI BN, Godoy-Brewer G, Parian AM, Noorian S, et al
     Dietary Interventions for the Treatment of Inflammatory Bowel Diseases: An Updated Systematic Review and Meta-analysis.
     Clin Gastroenterol Hepatol. 2023;21:2508-2525.
     PubMed     Abstract available
     
     
     
244. HALMA JC, Cristoferi L, Carbone M
     The Time is Ripe for a Randomized Controlled Trial of Oral Vancomycin in Primary Sclerosing Cholangitis.
     Clin Gastroenterol Hepatol. 2023;21:2699-2700.
     PubMed    
     
     
     
245. ATIA O, Benchimol EI, Ledderman N, Greenfeld S, et al
     Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study.
     Clin Gastroenterol Hepatol. 2023;21:2639-2648.
     PubMed     Abstract available
     
     
     
246. WANG M, Auerbach A, Oreper SM, Hohmann SF, et al
     Leveraging a New ICD-10 Diagnosis Code to Characterize Hospitalized Patients With Primary Sclerosing Cholangitis.
     Clin Gastroenterol Hepatol. 2023;21:2692-2694.
     PubMed    
     
     
     
247. MEYER A, Rios P, Drouin J, Weill A, et al
     Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children.
     Clin Gastroenterol Hepatol. 2023;21:2679-2681.
     PubMed    
     
     
     
248. XU L, He B, Sun Y, Li J, et al
     Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study.
     Clin Gastroenterol Hepatol. 2023 Sep 1:S1542-3565(23)00662.
     PubMed     Abstract available
     
     
     August 2023
249. ANG J, Berggreen P, Couto J, Goh L, et al
     Principles to advance value in inflammatory bowel disease: a collaborative payer-provider framework.
     Clin Gastroenterol Hepatol. 2023 Aug 14:S1542-3565(23)00628.
     PubMed    
     
     
     
250. ZHOU A, Srinivasan A, Vasudevan A
     Biologic choice should be guided by disease severity not malignancy in patients with inflammatory bowel disease.
     Clin Gastroenterol Hepatol. 2023 Aug 3:S1542-3565(23)00581.
     PubMed    
     
     
     
251. DAMAS OM, Maldonado-Contreras A
     Breaking Barriers in Dietary Research: Strategies to Diversify Recruitment in Clinical Studies and Develop Culturally Tailored Diets for Hispanic Communities Living With Inflammatory Bowel Disease.
     Clin Gastroenterol Hepatol. 2023;21:2169-2173.
     PubMed    
     
     
     
252. BUISSON A, Nachury M, Reymond M, Yzet C, et al
     Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
     Clin Gastroenterol Hepatol. 2023;21:2338-2346.
     PubMed     Abstract available
     
     
     
253. LOFTUS EV JR, Paul S, Roblin X
     Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude.
     Clin Gastroenterol Hepatol. 2023;21:2193-2194.
     PubMed    
     
     
     July 2023
254. BRENNER EJ, Zhang X, Long MD, Dubinsky MC, et al
     High Use of Estrogen-based Contraceptives in Young Women with Inflammatory Bowel Disease in the United States.
     Clin Gastroenterol Hepatol. 2023 Jul 21:S1542-3565(23)00541.
     PubMed    
     
     
     
255. WARD D, Andersen NN, Gortz S, Iversen AT, et al
     Tumour necrosis factor inhibitors in inflammatory bowel disease and risk of immune mediated inflammatory diseases.
     Clin Gastroenterol Hepatol. 2023 Jul 11:S1542-3565(23)00532.
     PubMed     Abstract available
     
     
     
256. DEEPAK P, Barnes EL, Shaukat A
     Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions.
     Clin Gastroenterol Hepatol. 2023;21:1681-1686.
     PubMed    
     
     
     
257. BOURGONJE AR, Otten AT
     The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?
     Clin Gastroenterol Hepatol. 2023;21:1971-1972.
     PubMed    
     
     
     
258. KHAN N, Mahmud N, Patel M, Sundararajan R, et al
     Incidence of Long COVID and Impact of Medications on the Risk of Developing Long COVID in a Nationwide Cohort of IBD Patients.
     Clin Gastroenterol Hepatol. 2023;21:1960-1962.
     PubMed    
     
     
     
259. FLUXA D, Stocchi L, Hashash JG
     Rectal Cuff Adenocarcinoma: Rare Complication in Patients with Ileal Pouch-Anal Anastomosis.
     Clin Gastroenterol Hepatol. 2023;21:A41-A42.
     PubMed    
     
     
     June 2023
260. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
     Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
     Clin Gastroenterol Hepatol. 2023 Jun 28:S1542-3565(23)00496.
     PubMed     Abstract available
     
     
     
261. COLOMBEL JF, Sands BE, Gasink C, Yeager B, et al
     Evolution of symptoms after ustekinumab induction therapy in patients with Crohn's disease.
     Clin Gastroenterol Hepatol. 2023 Jun 28:S1542-3565(23)00499.
     PubMed     Abstract available
     
     
     
262. KHANNA R, Ma C, Hogan M, Zou G, et al
     Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
     Clin Gastroenterol Hepatol. 2023 Jun 10:S1542-3565(23)00453.
     PubMed     Abstract available
     
     
     
263. BEN-HORIN S, Salomon N, Karampekos G, Viazis N, et al
     Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial.
     Clin Gastroenterol Hepatol. 2023 Jun 9:S1542-3565(23)00445.
     PubMed     Abstract available
     
     
     
264. HABASH N, Abash I
     Response to the letter to the editor "Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.".
     Clin Gastroenterol Hepatol. 2023 Jun 9:S1542-3565(23)00455.
     PubMed    
     
     
     
265. BARNES EL, Long MD, Raffals L, Isaacs K, et al
     Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch.
     Clin Gastroenterol Hepatol. 2023;21:1663-1666.
     PubMed     Abstract available
     
     
     
266. FLISS ISAKOV N, Kornblum J, Zemel M, Cohen NA, et al
     The Effect of the Crohn's Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study.
     Clin Gastroenterol Hepatol. 2023;21:1654-1656.
     PubMed     Abstract available
     
     
     May 2023
267. HU W, Liao X, Chen Y
     Is it a case of ileal Crohn's disease?
     Clin Gastroenterol Hepatol. 2023 May 26:S1542-3565(23)00385.
     PubMed    
     
     
     
268. KARIME C, Hashash JG, Farraye FA
     Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.
     Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00348.
     PubMed    
     
     
     
269. YU A, Ha NB, Shi B, Cheng YW, et al
     Real-World Experience with Tofacitinib Dose De-escalation in Patients with Moderate and Severe Ulcerative Colitis.
     Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00344.
     PubMed     Abstract available
     
     
     
270. HUTFLESS S, Jasper RA, Chen PH, Joseph S, et al
     Burden of Crohn's Disease in the United States Medicaid Population, 2010 - 2019.
     Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00346.
     PubMed     Abstract available
     
     
     
271. NEWMAN KL, Chedid VG, Boden EK
     A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals.
     Clin Gastroenterol Hepatol. 2023;21:1127-1133.
     PubMed    
     
     
     
272. DAI C, Jiang M, Huang YH
     Appendectomy and Future Risk of Microscopic Colitis: Correlation or Causation?
     Clin Gastroenterol Hepatol. 2023;21:1376-1377.
     PubMed    
     
     
     
273. DE SOUSA HT, Gullo I, Magro F
     Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue.
     Clin Gastroenterol Hepatol. 2023;21:1378-1380.
     PubMed    
     
     
     
274. KAYAL M, Ungaro RC, Bader G, Colombel JF, et al
     Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data.
     Clin Gastroenterol Hepatol. 2023;21:1348-1350.
     PubMed     Abstract available
     
     
     April 2023
275. OLEN O, Smedby PKE, Erichsen R, Pedersen PL, et al
     Increasing risk of lymphoma over time in Crohn's disease but not in ulcerative colitis: a Scandinavian cohort study.
     Clin Gastroenterol Hepatol. 2023 Apr 13:S1542-3565(23)00268.
     PubMed     Abstract available
     
     
     
276. BONESCHANSKER L, Ananthakrishnan AN
     Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real world data.
     Clin Gastroenterol Hepatol. 2023 Apr 7:S1542-3565(23)00248.
     PubMed    
     
     
     
277. SOLITANO V, Facciorusso A, Jess T, Ma C, et al
     Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
     Clin Gastroenterol Hepatol. 2023;21:907-921.
     PubMed     Abstract available
     
     
     
278. MENDALL MA
     Obesity and Risk of Crohn's Disease Half the Story.
     Clin Gastroenterol Hepatol. 2023;21:1121-1122.
     PubMed    
     
     
     March 2023
279. WETWITTAYAKHLANG P, Golovics PA, Gonczi L, Lakatos L, et al
     Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis:A Population-based Cohort between 1977-2020.
     Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00230.
     PubMed    
     
     
     
280. CONSTANTINE-COOKE N, Monterrubio-Gomez K, Plevris N, Derikx LAAP, et al
     Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease.
     Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00234.
     PubMed     Abstract available
     
     
     
281. FITZPATRICK JA, Halmos EP, Machado PP, Gibson PR, et al
     Ultra-processed foods and risk of Crohn's disease: how much is too much?
     Clin Gastroenterol Hepatol. 2023 Mar 24:S1542-3565(23)00217.
     PubMed    
     
     
     
282. COHEN BL, Lincango E, Holubar SD
     How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery.
     Clin Gastroenterol Hepatol. 2023 Mar 16:S1542-3565(23)00147.
     PubMed    
     
     
     
283. CARON B, Ghosh S, Danese S, Peyrin-Biroulet L, et al
     Identifying, understanding and managing fecal urgency in inflammatory bowel diseases.
     Clin Gastroenterol Hepatol. 2023 Mar 9:S1542-3565(23)00172.
     PubMed     Abstract available
     
     
     
284. FRIEDBERG S, Choi D, Hunold T, Choi NK, et al
     Upadacitinib is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
     Clin Gastroenterol Hepatol. 2023 Mar 8:S1542-3565(23)00173.
     PubMed     Abstract available
     
     
     
285. SAEVIK F
     Prediction of postoperative recurrence in Crohn's disease: where do we go from here?
     Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00170.
     PubMed    
     
     
     
286. TABATABAVAKILI S, Targownik LE
     Can an Inspiration Around Perspiration Lead to an Innovation In IBD Management?
     Clin Gastroenterol Hepatol. 2023;21:617-618.
     PubMed    
     
     
     
287. TE GROEN M, Hoentjen F
     Confirming Effectiveness of Endoscopic Colon Cancer Screening in Inflammatory Bowel Disease: The Puzzle Remains Unsolved?
     Clin Gastroenterol Hepatol. 2023;21:850-851.
     PubMed    
     
     
     
288. VAN DEN BERGHE N, Verstockt B, Vermeire S, Thomas D, et al
     Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
     Clin Gastroenterol Hepatol. 2023;21:838-840.
     PubMed    
     
     
     September 2022
289. OKAFOR PN, Dahlen A, Youssef M, Olayode A, et al
     Environmental Pollutants are Associated with Irritable Bowel Syndrome in a Commercially Insured Cohort of California Residents.
     Clin Gastroenterol Hepatol. 2022 Sep 30. pii: S1542-3565(22)00923.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum